Page 203 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman
P. 203
45. International Collaboration of Epidemiological Studies of Cervical C. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119(5):1108-24.
46. Kim JW, Song SH, Jin CH, Lee JK, Lee NW, Lee KW. Factors affecting the clearance of high-risk human papillomavirus infection and the progression of cervical intraepithelial neoplasia. J Int Med Res. 2012;40(2):486-96.
47. Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2013;108(1):234-9.
48. Husseinzadeh N, Davenport SM. Role of toll-like receptors in cervical, endometrial and ovarian cancers: a review. Gynecol Oncol. 2014;135(2):359-63.
49. Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther. 2017;2:17055.
50. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27(7):571-7.
51. Richards KH, Wasson CW, Watherston O, Doble R, Blair GE, Wittmann M, et al. The human papillomavirus (HPV) E7 protein antagonises an Imiquimod-induced inflammatory pathway in primary human keratinocytes. Sci Rep. 2015;5:12922.
52. Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol. 2007;157 Suppl 2:8-13.
53. DeCarlo CA, Rosa B, Jackson R, Niccoli S, Escott NG, Zehbe I. Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol. 2012;2012:785825.
54. Hasimu A, Ge L, Li QZ, Zhang RP, Guo X. Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer.
2011;30(5):344-50.
55. Scott ME, Ma Y, Farhat S, Moscicki AB. Expression of nucleic acid-sensing Toll-like receptors
10
Discussion
predicts HPV16 clearance associated with an E6-directed cell-mediated response. Int J
Cancer. 2015;136(10):2402-8.
56. van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen
C, Drijfhout JW, et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res. 2005;11(14):5273-80.
57. Todd RW, Steele JC, Etherington I, Luesley DM. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia. Gynecol Oncol. 2004;92(1):167-74.
58. Terlou A, van Seters M, Kleinjan A, Heijmans-Antonissen C, Santegoets LA, Beckmann I, et al. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int J Cancer. 2010;127(12):2831-40.
59. Jones SEF, Hibbitts S, Hurt CN, Bryant D, Fiander AN, Powell N, et al. Human Papillomavirus DNA Methylation Predicts Response to Treatment Using Cidofovir and Imiquimod in Vulval Intraepithelial Neoplasia 3. Clin Cancer Res. 2017;23(18):5460-8.
60. Halec G, Scott ME, Farhat S, Darragh TM, Moscicki AB. Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2. Int J Cancer. 2018.
201
